GSTM1 and chronic kidney disease: ASCEND-NHQ demonstrated that daprodustat (n = 307) was superior to placebo (n = 307) in increasing Hb levels among adults with CKD stages 3–5 not receiving dialysis. Greater improvements in fatigue were also shown for patients receiving daprodustat compared with placebo. The mean change in SF-36 score was also higher at week 28 in patients receiving daprodustat than those who received placebo.